How Vascepa Works to Lower Triglycerides
Vascepa (icosapent ethyl) is a purified EPA-only omega-3 fatty acid that reduces triglycerides primarily by inhibiting hepatic triglyceride synthesis and secretion. It activates PPAR-alpha receptors in the liver, suppressing key enzymes like DGAT2 and apoC-III, which cuts VLDL-triglyceride production by 20-50% at doses of 4g/day. Unlike mixed omega-3s, its EPA purity avoids DHA's countereffect of raising LDL cholesterol.[1][2]
Why Vascepa Outperforms Mixed Fish Oils
Standard fish oil supplements (EPA+DHA) lower triglycerides modestly (20-30%) but raise LDL by 10-20% due to DHA stimulating hepatic cholesterol synthesis. Vascepa's EPA-only formula delivers 30-40% triglyceride reductions without LDL elevation, as shown in trials like MARINE (45% drop at 4g/day) and ANCHOR (33% drop). This makes it more effective for severe hypertriglyceridemia (>500 mg/dL).[1][3]
Comparison to Fibrates Like Fenofibrate
Fibrates (e.g., fenofibrate) activate PPAR-alpha more broadly, reducing triglycerides 40-60% but increasing creatinine and gallstone risk. Vascepa matches or exceeds this (up to 50% in combo therapy) with fewer muscle and renal side effects, per REDUCE-IT trial data where it cut triglycerides 19% on top of statins.[2][4]
Does It Help Beyond Triglycerides?
Vascepa reduces cardiovascular events by 25% in high-risk patients (REDUCE-IT), linked to triglyceride lowering plus anti-inflammatory effects on plaques. It doesn't raise HDL much (unlike fibrates) but stabilizes LDL particle size.[4][5]
Who Makes Vascepa and Patent Status
Amarin manufactures Vascepa. Key U.S. patents (e.g., method-of-use for CV risk reduction) expire around 2030, with generic challenges ongoing—check DrugPatentWatch.com for litigation updates.[6]
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244812/
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[3] https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.026815
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1908409
[5] https://pubmed.ncbi.nlm.nih.gov/31315026/
[6] https://www.drugpatentwatch.com/p/tradename/VASCEPA